The study, led by Henry Omar Herrera of Case Western Reserve University together with colleagues at University Hospitals Cleveland Medical Center and Albert Einstein College of Medicine, set out to answer a deceptively simple question. When Hispanic or Latino patients are diagnosed with psoriasis, what is their subsequent risk of developing new-onset metabolic conditions such as type 2 diabetes, hypertension, dyslipidemia, obesity-related disorders, and metabolic syndrome? The question matters because psoriasis is already recognized as an independent risk factor for metabolic disease in the general population, but the vast majority of the evidence base has been built on cohorts of European descent.

The biological rationale for the psoriasis-metabolism connection is well established. Psoriasis is driven by a sustained activation of the immune system, particularly T cells and inflammatory signaling molecules such as tumor necrosis factor alpha, interleukin-17, and interleukin-23. These cytokines do not confine their effects to the skin. They circulate systemically, promoting insulin resistance in muscle and liver tissue, altering lipid metabolism, and encouraging the low-grade vascular inflammation that underlies atherosclerosis. Over months and years, this chronic inflammatory state can tip patients toward the metabolic syndrome cluster of abdominal obesity, elevated triglycerides, low HDL cholesterol, high blood pressure, and impaired fasting glucose.

Hispanic and Latino populations in the United States carry a distinct baseline metabolic profile that makes this interaction especially consequential. National surveillance data cited by the authors show that Hispanic Americans experience higher rates of diabetes and several of its complications compared with non-Hispanic white Americans. Large epidemiological surveys, including the landmark JAMA analysis of diabetes prevalence by race and ethnicity from 2011 to 2016, have documented that the burden of diagnosed and undiagnosed diabetes is disproportionately heavy in this community. Layering the systemic inflammation of psoriasis on top of that elevated baseline risk creates a scenario in which even a modest additional inflammatory push could translate into a meaningful increase in new metabolic diagnoses.

Yet, as the authors and prior reviewers have noted, Hispanic and Latino patients with psoriatic disease have historically been a blind spot in the literature. A comprehensive review of psoriatic disease in the US Latino population published in the American Journal of Clinical Dermatology highlighted how little controlled data exist on disease presentation, treatment response, and comorbidity trajectories in this group. Dermatology registries and biologic trials tend to enroll predominantly white participants, which means that risk estimates derived from those datasets may simply not apply to other populations. Genetic ancestry, patterns of adipose tissue distribution, dietary and occupational factors, access to care, and differences in how aggressively comorbidities are screened for can all shift the relationship between skin inflammation and metabolic outcomes.

The retrospective cohort design of the new analysis reflects both the practicality and the limitations of studying these questions with real-world medical records. Rather than randomizing patients to interventions, the researchers looked backward through clinical data, identifying Hispanic or Latino patients with a diagnosis of psoriasis vulgaris and tracking whether they went on to receive new diagnoses of metabolic comorbidities during follow-up. Retrospective cohorts of this kind are powerful for generating incidence estimates and hypothesis-generating risk signals in populations that are rarely captured in prospective trials, but they depend on the completeness and accuracy of the underlying records, and they can be vulnerable to confounding by factors such as body mass index, medication use, and healthcare utilization patterns.

Why does this matter clinically? Dermatologists are increasingly viewed as the first line of defense against the systemic consequences of psoriasis. A patient who presents with plaques on the elbows and scalp is not just a cosmetic or comfort concern; that patient carries a quantifiably elevated lifetime risk of myocardial infarction, stroke, and diabetes. Guidelines from several dermatology societies now recommend that patients with moderate to severe psoriasis undergo periodic screening for metabolic syndrome components, including blood pressure, fasting glucose or hemoglobin A1c, and lipid panels. If Hispanic and Latino patients face a higher trajectory of new-onset metabolic disease after a psoriasis diagnosis, then screening intensity, lifestyle counseling, and early referral to primary care or endocrinology may need to be calibrated differently for this population.

The study also arrives at a moment when the demographics of psoriasis in the United States are shifting. Hispanic Americans represent a large and rapidly growing share of the national population, and psoriasis affects an estimated three percent of US adults overall. Simple arithmetic dictates that the absolute number of Hispanic and Latino individuals living with psoriatic disease will continue to climb. If the comorbidity burden in this group is systematically underestimated, health systems will be caught unprepared for a wave of cardiovascular and diabetic complications that could have been anticipated and, in part, prevented. Health disparities research of this type is therefore not merely academic; it is a matter of resource allocation, screening policy, and ultimately lives saved.

There are also important mechanistic questions raised by population-specific risk research. Adiposity patterns differ across ancestral groups, with some populations showing greater visceral fat deposition at the same body mass index, and visceral fat is a particularly potent source of the inflammatory adipokines that synergize with psoriasis-related cytokines. Genetic variants influencing both immune signaling and lipid metabolism vary in frequency across populations. Socioeconomic factors, including food environments, occupational stress, and barriers to consistent healthcare, further modulate the observed risk. Disentangling these strands requires exactly the kind of targeted cohort work that the Cleveland and Bronx-based team has begun, and it argues for larger, multi-center, prospective studies with granular data on ancestry, disease severity measured by body surface area or PASI scores, and longitudinal metabolic laboratory values.

For now, the practical message for clinicians and patients is clear. Psoriasis in Hispanic and Latino patients should prompt the same vigilance toward metabolic health that the field has learned to apply in other populations, and quite possibly more. Patients should be aware that their skin condition is connected to their heart and metabolic health, and that controlling systemic inflammation, maintaining a healthy weight, staying physically active, and keeping up with metabolic screening are all part of managing psoriasis in the twenty-first century. As the evidence base grows more inclusive, the hope is that risk prediction and preventive care will finally serve every population equally, rather than only those who have historically filled the clinical trials.

Subject of Research: Risk of new-onset metabolic comorbidities in Hispanic or Latino patients with psoriasis vulgaris

Article Title: Risk of new-onset metabolic comorbidities in hispanic or latino patients with psoriasis vulgaris: a retrospective cohort analysis

Article References: Herrera, H. O., Nolasco, B., Sánchez-Feliciano, A., & Bordeaux, J. (2026). Risk of new-onset metabolic comorbidities in hispanic or latino patients with psoriasis vulgaris: a retrospective cohort analysis. Archives of Dermatological Research, 318(1), Article 512. https://doi.org/10.1007/s00403-026-04971-3

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04971-3

Keywords: psoriasis, psoriasis vulgaris, Hispanic health, Latino health, metabolic syndrome, type 2 diabetes, cardiovascular risk, dermatology, health disparities, retrospective cohort, chronic inflammation, comorbidities

PEDF is a 50-kilodalton glycoprotein that was first identified in the conditioned media of cultured human retinal pigment epithelial cells in the early 1990s, where it displayed potent neuronal differentiative activity. Subsequent work revealed that it belongs to the serpin family of proteins, although it lacks the protease-inhibiting function that characterizes most serpins. Instead, PEDF has earned a reputation as one of the most powerful endogenous inhibitors of angiogenesis known to biology, exceeding even the effects of thrombospondin-1 in some assay systems. Beyond its vascular effects, PEDF participates in metabolism, acting as an adipokine released from adipose tissue and influencing insulin sensitivity, which is one reason researchers suspected it might connect psoriasis with the metabolic syndrome.

The rationale for the Egyptian study rested on two converging lines of evidence. First, psoriasis is fundamentally a disease of disordered angiogenesis: the dermal papillae of psoriatic plaques are packed with dilated, tortuous capillaries, and vascular endothelial growth factor and other pro-angiogenic mediators are abundantly expressed in lesional skin. Second, earlier reports had suggested that circulating PEDF concentrations were elevated in psoriasis patients, raising the possibility that the protein could serve as a biomarker linking the skin disease to cardiovascular and metabolic comorbidity. However, few studies had simultaneously examined serum levels and tissue expression, and none had rigorously tested whether PEDF tracks with clinical severity or metabolic status in the same cohort.

To address these gaps, the team, led by dermatologist Amr Abdelhamed, enrolled 26 patients with psoriasis vulgaris and 26 age- and sex-matched healthy controls. Each patient underwent a detailed clinical assessment, including calculation of the Psoriasis Area and Severity Index, the standard composite measure that grades erythema, induration, and desquamation across body regions. The investigators also screened participants for metabolic syndrome using established diagnostic criteria encompassing waist circumference, triglycerides, high-density lipoprotein cholesterol, blood pressure, and fasting glucose. Blood samples were drawn for serum PEDF quantification by enzyme-linked immunosorbent assay, while punch biopsies were taken from both lesional plaque skin and peri-lesional, normally appearing skin for immunohistochemical staining of PEDF expression.

The serum results defied expectations. Median serum PEDF concentration in the psoriasis group was 21.5 nanograms per milliliter, with a range spanning 13 to 162, compared with 22.2 nanograms per milliliter, ranging from 7 to 193, in the controls. The difference was statistically non-significant, with a p-value of 0.261, meaning that circulating PEDF offered no meaningful discrimination between patients and healthy individuals in this cohort. This finding stands in tension with earlier studies that reported elevated serum PEDF in psoriasis, and it underscores how cohort characteristics, assay methodology, and sample size can shape biomarker conclusions in dermatology research.

The tissue data told a far more striking story. Immunohistochemical analysis revealed a median PEDF expression score of 1.4, on a scale ranging from 0.5 to 2.2, in lesional psoriatic skin. That figure was dramatically lower than the median of 5, ranging from 2 to 5.5, observed in the peri-lesional skin of the same patients, and lower still than the median of 5.8, ranging from 5.7 to 7.3, in the skin of healthy controls. Both comparisons yielded p-values below 0.001, indicating differences that are extremely unlikely to have arisen by chance. In other words, the very skin that bears the hallmark of psoriasis is markedly depleted of one of the body’s chief anti-angiogenic defenses, while the skin immediately adjacent to the plaques retains near-normal expression.

This spatial gradient carries important mechanistic implications. Angiogenesis in psoriasis is thought to be fueled by an imbalance between pro-angiogenic drivers, such as vascular endothelial growth factor, interleukin-8, and angiopoietins released by keratinocytes and inflammatory cells, and anti-angiogenic brakes like PEDF and thrombospondin-1. The new data suggest that the loss of the PEDF brake is a local phenomenon confined to diseased tissue rather than a systemic shift detectable in the blood. That localization is consistent with the histopathology of psoriatic plaques, where elongated and dilated capillaries in the papillary dermis supply nutrients to the hyperproliferative epidermis above. It also aligns with experimental work showing that topical application of PEDF-derived anti-angiogenic peptides can ameliorate psoriasis-like skin changes in animal models.

Perhaps the most clinically consequential negative finding concerned the metabolic syndrome. Psoriasis patients are known to carry an elevated burden of obesity, dyslipidemia, hypertension, and insulin resistance, and PEDF has been implicated in insulin resistance in obesity, with adipose-derived PEDF rising as fat mass expands. Yet in this study, neither serum nor tissue PEDF levels correlated with the presence or absence of metabolic syndrome, nor with the PASI score, with all corresponding p-values exceeding 0.05. The authors also explored univariate correlations between PEDF levels and various histopathological features, reported in supplementary tables, without uncovering significant associations. The disconnect suggests that PEDF is unlikely to serve as a convenient blood-based biomarker tying psoriasis severity to cardiometabolic risk, at least in populations resembling this one.

Several caveats temper the conclusions. The sample size of 26 patients per group was modest, calculated with power analysis software but still vulnerable to type II error, particularly for correlation analyses that require larger cohorts to detect weak associations. The cross-sectional design captures a single time point, so it cannot establish whether reduced tissue PEDF is a cause or a consequence of plaque formation. Serum PEDF concentrations also varied enormously within both groups, spanning nearly an order of magnitude, which may reflect confounders such as body composition, age, and comorbid disease that a larger study could adjust for more thoroughly. Longitudinal follow-up of patients during effective therapy would help determine whether PEDF expression rebounds as plaques resolve.

Even so, the study sharpens the picture of psoriasis as a disease in which the local vascular microenvironment is decisively tilted toward vessel growth. The near absence of PEDF in lesional skin, contrasted with its preservation in neighboring tissue, provides a measurable target for therapeutic intervention and reinforces the rationale for anti-angiogenic strategies in dermatology. It also serves as a cautionary tale about biomarker research: a molecule can be abundant in the circulation yet irrelevant to the diseased tissue, and only paired serum-and-tissue studies can reveal that distinction. As researchers continue to map the angiogenic circuitry of psoriasis, PEDF now stands as a locally silenced guardian whose restoration might one day complement existing anti-inflammatory treatments.

Subject of Research: Serum and tissue levels of the anti-angiogenic protein PEDF in patients with psoriasis vulgaris

Article Title: Evaluation of serum and tissue levels of pigment epithelium-derived factor (PEDF) in patients with psoriasis vulgaris

Article References: Evaluation of serum and tissue levels of pigment epithelium-derived factor (PEDF) in patients with psoriasis vulgaris. (n.d.). https://doi.org/10.1007/s00403-026-04887-y

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04887-y

Keywords: psoriasis vulgaris, PEDF, angiogenesis, metabolic syndrome, PASI score, serum biomarkers, immunohistochemistry, lesional skin, dermatology research, Archives of Dermatological Research, Evaluation, serum